<DOC>
	<DOCNO>NCT02163187</DOCNO>
	<brief_summary>The purpose study evaluate whether medical device/implant ( InterStimTM ) help patient normal bowel movement . The InterStimTM device neuromodulating device . Neuromodulation way change activity nervous system use electrical stimulation . InterStimTM FDA approve help people hard time control bowl movement . This call fecal incontinence.The device place near nerve root low back . It work manner similar pacemaker release electrical stimulation trigger S3 nerve root . When place , initially test make sure work use temporary wire , successful , device permanently implant .</brief_summary>
	<brief_title>Sacral Neuromodulation ( SNM ) With InterStimTM Bowel Dysfunction Following Surgery Rectal Cancers With Sphincter Preservation</brief_title>
	<detailed_description>This single-blind randomize crossover study . After provide write informed consent , eligible patient undergo initial stimulation procedure temporary lead ( Step 1 Wire Stimulation ) . The simulation perform determine efficacy device permanent implant place . This stimulation take place period 7-14 day ( +/-3 day ) . Because procedure do OR , window time allow optimization device coordination operate room schedule . This time period use prior trial . Typically bowel improvement see relatively quickly , range affect assessment BFI . After Wire Implantation occur , patient evaluate next 7-14 day ( +/- 3 day ) complete BFI questionnaire . If BFI improvement &lt; = 4 point wire remove operating room , patient offer standard care , patient long part study . Based prior data , would like give many patient possible opportunity enrollment result choose 4 point BFI change minimum criterion response . Our group see change BFI around 5-6 clinically significant , low threshold slightly . If patient 's BFI improve ≥ 4 point , patient proceed randomize phase ( Step 2-Implantation ) study . Patients proceed Step 2- Implantation , return operate room implantation permanent device . While operate room randomly assign either device stimulation ( Group A ) device stimulation ( Group B ) first 4 week ( +/-3 day ) . Patients return clinic 2 week later cross arm ( Step 3-Crossover ) device stimulation set . Patients come back clinic within 7 day ( +/- 7 day ) Crossover device check optimization .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<criteria>History rectal cancer neoplastic polyp ( i.e . intramucosal carcinoma , carcinoma situ ) BFI score must meet least one criterion : Total BFI &lt; 50 Dietary subscale &lt; 11 Frequency subscale &lt; 19 Urgency subscale &lt; 12 English speaking Patients ≥18 year old . age Sphincterpreserving surgery ≥ 12 month restoration bowel continuity Locally recurrent metastatic disease Immune suppressive medication Seizure disorder Prior sacral/lower spinal surgery Congenital Spinal defect/Paraplegia Rectal prolapse IBD/Crohn 's Pregnancy Active anal/rectal abscess Pacemaker electronic implant device Immediate need MRI At time wire stimulation procedure , patient exclude surgeon unable place temporary stimulating lead Inability commit local follow device management .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Neuromodulation ( SNM )</keyword>
	<keyword>sphincter preservation</keyword>
	<keyword>rectal polyp</keyword>
	<keyword>InterStimTM</keyword>
	<keyword>14-100</keyword>
</DOC>